The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 2, 2007, Pages 211-218

  Wang, Linrun R ^a   Wu, Xiuhua H ^a   Huang, Mingzhu Zh ^a   Cai, Jie ^a   Xu, Nong ^a   Liu, Jian ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Efficacy; Gemcitabine; Non small cell lung cancer; Toxicity

Indexed keywords

CARBOPLATIN; GEMCITABINE; GEMZARS; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; RASH; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SIDE EFFECT; STATISTICAL ANALYSIS; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TUMOR GROWTH;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE;

EID: 34248396059     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0363-x     Document Type: Article

References (29)

1. Hertel LW, Kroin JS, Misner JW et al (1988) Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2-difluoro-D-ribofuranosyl nucleosides. J Org Chem 53:2406-2409
2. Yokoyama A, Nakai Y, Yoneda S et al (1997) Activity of gemcitabine in the treatment of patients with non-small-cell lung cancer: a multicenter phase study. Anti-cancer Drugs 8:574-581
3. Pollera CF, Ceribelli A, Crecco M et al (1994) Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase study. Ann Oncol 5:182-184
4. Burris HA, Moore MJ, Anderson J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413
5. Carmichael J, Possinger K, Phillip P et al (1995) Advanced breast cancer. A phase 2 trial with gemcitabine. J Clin Oncol 13:2731-2736
6. Heinemann V, Hertel LW, Grindey GB et al (1988) Comparison of the cellular pharmacokinetics and toxicity of 2′,2″- difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 48:4024-4031
7. Heinemann V, Xu Y-Z, Chubb S, et al (1990) Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 38:567-572
8. Huang P, Chubb S, Hertel LW et al (1991) Action of 2′,2′- difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110-6117
9. Huang P, Plunkett W (1995) Fludarabine and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 36:181-188
10. Grunewald R, Kantarjian H, Keating MJ et al (1990) Pharmacologically directed design of the dose rate and schedule of 2′,2′- difluorodeoxycytidine(gemcitabine) administration in leukemia. Cancer Res 50:6823-6826
11. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98
12. Sederholm C (2002) Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer study group. Semin Oncol 29:50-54
13. Thomas P, Robinet G, Gouva S et al (2006) Randomized multicenter phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small-cell lung cancer GFPC 1999-2001 study (Groupe francais de pneumo-cancerologie). Lung Cancer 51:105-114
14. Zatloukal P, Petruzelka L, Zemanova M et al (2003) Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small-cell lung cancer: a phase randomized trial. Lung Cancer 41:321-331
15. Manuel D, Laura GE, Ana L (2002) A phase II trial of a two hour infusion of gemcitabine with carboplatin for advanced non-small-cell lung cancer (NSCLC). Ann Oncol, 13(suppl. 5):143
16. Schmid P, Akrivakis K, Flath B et al (1999) Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 10:625-631
17. Wang LR, Huang MZ, Xu N, et al (2005) Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer. J Zhejiang Univ Sci B 6:446-450
18. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
19. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
20. Eisenhauer EA, Vermorken JB (1998) The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 55:5-30
21. Noble S, Goa KL (1997) Gemcitabine. A review of its pharmacology and clinical potential in non-small-cell lung cancer and pancreatic cancer. Drugs 54:447-472
22. Fogli S, Danesi R, De Braud F et al (2001) Drug distribution and pharmacokinetic/pharmaco-dynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. Ann Oncol 12:1553-1559
23. Rowland M, Tozer TN (1995) (Third edition) Clinical Pharmacokinetics: Concepts and Applications. Baltimore, Williams and Wilkins, Maryland
24. Tempero M, Plunkett W, Ruiz van H et al (2003) Randomized phase II comparison of dose-intense Gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402-3408
25. Domine M, Estevez L, Leon A et al (2002) Phase II trial of a two-hour infusion of gemcitabine with carboplatin for advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21:225b
26. Rudd RM, Gower NH, Eisen TG et al (2005) Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 23:142-153
27. Kroep JR, Giaccone G, Voorn DA et al (1999) Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol 17:2190
28. Yonemori K, Ueno H, Okusaka T et al (2005) Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 11:2620-2624
29. Soo RA, Wang LZ, Tham LS et al (2006) A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Ann Oncol 17:1128-1133